In the course of our study on optically active azolonebased antifungal azoles, we selected 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone (1: TAK-456) as a candidate for clinical trials (Chart 1). In previous reports, we described the stereocontrolled synthesis of TAK-456 1) and the antifungal activities in vitro and in vivo.
Invasive aspergillosis still remains resistant to antifungal chemotherapy, although injectable amphotericin B has been used for the treatment of this disease in spite of the severe toxicity.
4) It is, therefore, considered that an injectable formulation of TAK-456 would have potential in the clinical treatment of this serious disease. We attempted to prepare an injectable solution of TAK-456 with sufficient concentration for experimental and clinical uses, but several trials by addition of pharmacologically acceptable cosolvents and/or excipients were unsuccessful because of the poor water-solubility (0.005 mg/ml) of TAK-456. Then, we turned our efforts to preparing a water-soluble prodrug of TAK-456. Bodor et al. has described the general concept of "soft drugs" or "prodrugs", for modifying the physicochemical properties, including water-solubility and pharmacokinetic profiles, of drugs containing a tertiary nitrogen atom by quarternizing them to the corresponding ammonium salts with a enzymatically and/or chemically labile group. 5) Thus, we designed the quaternary triazolium salts depicted by the general formula 2. The prodrug strategy is represented by the scheme shown in Chart 2. Compounds 2, which could be prepared by alkylation of TAK-456, might have enhanced water-solubility owing to their charged character and could be expected to be hydrolyzed enzymatically and/or non-enzymatically in vivo to generate the parent compound TAK-456. It was also expected that the water-solubility and the liability to hydrolysis would depend on the physicochemical properties of the substituent R. To search for a prodrug suitable for injectable formulation, we planned to prepare a series of compounds 2 with different physicochemical properties. We chose alkyl, alkoxy and substituted alkoxy groups (see Chart 2) for the substituent R and prepared the triazolium salts 2 ( Table 1) . In this paper, we describe the synthesis of 2 as well as the results of evaluations on their water-solubility, stability, hemolytic effect and antifungal activities.
Synthesis The water-soluble prodrugs (2a-g, i: Table  1 ) were prepared by alkylation of the parent compound 1 with halomethyl esters or halomethyl carbonates (4-6) in an aprotic polar solvent such as acetonitrile (MeCN) or acetone within a range of temperatures between 50 and 100°C as shown in Chart 3. In the case of reaction of 1 with 5 or 6, the resulting triazolium bromides or iodides were converted to the corresponding chlorides (2a, d, e, g, i) by anion-exchange with Dowex 1ϫ8 Cl Ϫ or mixing with aqueous saturated sodium chloride (NaCl) solution (brine). The hydroxypropoxy derivative 2h was prepared from the benzyloxypropoxy derivative 2j by catalytic hydrogenolysis with palladium on carbon (Pd-C). The compounds 2a-h, except 2i (amorphous), were obtained as crystals after purification Optically Active Antifungal Azoles. XII. Among the crystalline quaternary triazolium salts, the acetoxymethyl derivative 2a was obtained in two crystalline forms, i.e., the unhydrated form crystallized from EtOH-acetone and the hydrated form crystallized from water. The position of alkylation on the 1,2,4-triazole was assumed to be at the 4-nitrogen atom since Duffin et al. reported that quanternization of 1-substituted 1,2,4-triazoles generally occurs at the 4-position to give the corresponding 1,4-disubstituted triazolium salts.
6) The assignment of the 1,4-disubstituted triazolium structure was carried out using 2a by NMR measurement, i.e., the nuclear Overhauser and exchange spectroscopy (NOESY) and 1 H-detected multiplebond heteronuclear multiple quantum coherrence (HMBC). 7) Thus, in NOESY of 2a, a nuclear Overhauser effect (NOE) between the methylene protons of the acetoxymethyl group and the 3-and 5-protons on the triazole ring was observed. On the other hand, HMBC of 2a showed C-H long range coupling between the methylene protons of the acetoxymethyl group and the 3-and 5-carbons on the triazole.
Water-Solubility and Stability The prodrugs for injectable use should have sufficient solubility and adequate stability in water to allow production of the injectable formulation. Therefore, the triazolium salts 2 were assessed for their solubility and stability in 5% glucose as an injectable carrier.
8) The solubilities (mg/ml) of 2b, d-i were measured by the following simple method: 5% glucose was added portionwise (0.1 ml aliquots) to compound 2 (1 mg) with shaking followed by sonication until a clear solution was obtained. The solubility (mg/ml) was calculated based on the amount of 5% glucose added. In the case of 2a, c, the solubilities were determined by another method: a mixture of 2 and 5% glucose was allowed to stand in a sonicator for 10 min at room temperature and the remaining solid (2) was A.P. a) 1a-g, i: yields based on the parent compound (2); 1h: yield of the deprotection reaction. b) Recrystallization solvent: EA, AcOEt; W, water; AC, acetone; ET, EtOH. c) Not measured. d) A.P.: Amorphous powder. e) The reaction was carried out in acetone. f) The reaction was carried out in MeCN. g) The product was purified by chromatography using a pre-packed column CPO-273LR (ODS). h) The product was purified by silica gel column chromatography. i) The product was purified by crystallization. j) Anion exchange was done with Dowex 1ϫ8 Cl Ϫ . k) Anion exchange was done by mixing with brine. filtered off using a 0.2 mm membrane filter. The concentration (solubility: mg/ml) of 2 in the filtrate was determined by HPLC based on the peak area. 9) On the other hand, the stabilities were measured by the following method: a 1-5 mg/ml solution of 2 in 5% glucose was allowed to stand for 1 d at room temperature and the relative % content of 1 formed by hydrolysis of 2 was determined by HPLC. 9) This % value was regarded as the stability of the prodrugs 2. The solubility and the stability results are shown in Table 2 .
Compounds 2 generally had good water-solubility (1.5-Ն10 mg/ml). Notably, compounds 2h, i, which have hydrophilic hydroxyl and acetoamino groups, respectively, revealed water-solubility higher than 10 mg/ml. In the case of 2a, the solubilities of two crystalline forms were somewhat different; i.e., 10 mg/ml for the unhydrated form and 4 mg/ml for the hydrated form.
The alkanoyl derivatives (2a-c) and the alkoxycarbonyl derivatives (2d-f) were considerably resistant to hydrolysis in 5% glucose (stability: 0.1-2.1%). Among these prodrugs (2a-f), the compounds having secondary and tertiary alkyl groups (2b, c, f: 0.3, 0.1, 0.3%, respectively) were found to be more stable than the compounds having unbranched alkyl groups (2a, d, e: 1.8, 2.1, 1.9%, respectively). On the other hand, 2g-i with hydrophilic moieties were considerably unstable (6.4-25.6%). Especially, the hydroxyl compound 2h showed the lowest stability (25.6%), which might be due to the neighboring group participation of the hydroxyl group accelerating the hydrolysis.
Biological Activity The in vitro antifungal activities of the triazolium salts 2 against C. albicans TA were compared with the parent compound 1 (TAK-456) and the non-prodrug quaternary salt 3 ( Table 3 ). The in vitro activities are expressed as the minimum inhibitory concentrations (MIC, mg/ml), which were determined by an agar-dilution method on RPMI 1640 medium under 20% CO 2 .
10) Compounds 2a- i (MICs, 0.016-0.5) were about ten times or more less potent than the parent compound 1 (MIC, 0.002-0.008). On the other hand, the N-methyl triazolium salt 3, which is stable to hydrolysis, was substantially inactive (MIC, Ͼ16). Therefore, it is considered that the antifungal activity of compound 2 is inherently weak and the observed activity could be due to a small amount of the parent compound 1, which is formed by hydrolysis in the assay medium during the experiment.
Four compounds 2a, c, d, f were evaluated for in vivo antifungal activity using C. albicans TA infected mice ( Table 3) . The test compounds (1 mmol/kg) were administered intravenously once, immediately after infection. The activity is expressed as the number (N) of survivors per total number of mice (nϭ5) on day 7 after infection and as the mean survival days (Day) of the mice which had died up to 7 d after infection. All of the prodrugs tested were found to exert strong protective effects (Nϭ1/5-3/5, Dayϭ4.5-6.0) against candidiasis comparable to that of the parent compound 1 (Nϭ2/5, Dayϭ4.3). These results of antifungal activities in vitro and in vivo suggested that compounds 2 are hydrolyzed to the parent compound 1 in blood after intravenous administration.
In general, some amphiphilic compounds such as quaternary salts, which contain both hydrophobic and hydrophilic moieties, have been known to induce hemolysis. Thus, compounds 2 were assessed for hemolytic activity using rat blood. Table 3 shows the % of hemolysis caused by compounds 2. Compounds 2g-i with the hydrophilic moieties were found to have low hemolytic activity (1.1-2.2%). Among the alkanoyl derivatives (2a-c) and the alkoxycarbonyl derivatives (2d-f), compounds 2b, c, e, f, possessing lipophilic alkyl or alkoxy groups showed high hemolytic activity (64-100%). On the other hand, the activity of compounds 2a, d that have smaller alkyl or alkoxyl groups, proved to be low. Especially, compound 2a bearing the acetoxymethyl group was substantially devoid of this effect (1.8%).
From the series of prodrugs, we selected 2a as the most promising compound for further evaluation.
In Vivo Antifungal Activity of 2a The in vivo antifungal activity of 2a against C. albicans TA and A. fumigatus 437 in mice was evaluated and compared with the parent compound 1 (TAK-456), fluconazole and itraconazole. C. albicans TA infected mice and A. fumigatus 437 infected neutropenic mice were used for the in vivo assay. In the in vivo assay against C. albicans TA, the test compounds were administered once, intravenously or orally, immediately after infection. On the other hand, in the case of the in vivo assay against A. fumigatus 437, the test compounds were administered intravenously or orally, once on the day of infection and twice daily on the following 2 d. The in vivo activity (Table  4) is expressed in terms of ED 50 (mg/kg, the dose of the test compound which allows 50% survival of the infected mice). The activity (ED 50 , 0.62 mg/kg) of 2a against C. albicans TA infection was comparable to those of 1 (ED 50 , 0.77 mg/kg) and fluconazole (ED 50 , 0.22-0.39 mg/kg), and superior to that of itraconazole (ED 50 , 5.19 mg/kg). Furthermore, in the therapeutic effect against aspergillosis in neutropenic mice, 2a showed a low ED 50 value (ED 50 , 4.49 mg/kg), comparable to that of 1 (ED 50 , 3.56 mg/kg), and remarkably superior to those of fluconazole (ED 50 , 179 mg/kg) and itraconazole (ED 50 , 19 mg/kg).
Pharmacokinetics of 2a
The in vitro half-lives of 2a were measured in the plasma of various animals, including mouse, rat and human. The results are shown in Table 5 . Compound 2a was hydrolyzed rapidly to form TAK-456 and the T-half-lives in vitro were about 5-6 min in the plasma of all the animals tested (mouse 5.1 min; rat 6.4 min; human 6.0 min). It is noteworthy that there was no species difference in hydrolysis.
This rapid conversion of 2a to TAK-456 was also confirmed in vivo using rats. Figure 1 shows the time course of the plasma concentrations of 2a and TAK-456 after intravenous administration of [
14 C]-2a (1 mg/kg). 12) As seen in Fig. 1, 2a was rapidly hydrolyzed with a T-half-life of 6 min and the parent compound TAK-456 appeared quickly. From the basis of the above in vitro and in vivo studies, 2a is expected to be converted smoothly to TAK-456 in humans. Based on the results of the evaluations described above, compound 2a (TAK-457) was designated as the injectable candidate for clinical trials. In conclusion, we identified a new antifungal prodrug TAK-457 for injectable use. This biologically labile quaternary triazolium salt had sufficient solubility and adequate stability for an injectable formulation and exhibited excellent therapeutic effects against candidiasis as well as aspergillosis in mice via intravenous administration. Detailed studies on the therapeutic effects against aspergillosis using various experimental models will be described in a separate paper.
13)

Experimental
Melting points were determined using a Yanagimoto melting point apparatus and are uncorrected. IR spectra were measured with a JASCO IR-810 spectrometer or a Shimazu FTIR-8200PC spectrometer. NMR spectra were recorded on Varian Gemini-200 and Bruker Avance DPX-300 spectrometers with tetramethylsilane as an internal standard. The following abbreviations are used: sϭsinglet, dϭdoublet, tϭtriplet, qϭquartet, mϭmultiplet, brϭ broad. The optical rotations were recorded with a JASCO DIP-181 or DIP-370 digital polarimeter.
Reactions were followed by TLC on Silica-gel 60 F 254 precoated TLC plates (E. Merck) or by HPLC using an ODS column (A-303, 4.6 mm i.d.ϫ250 mm, YMC Co., Ltd.). Standard work-up procedures were as follows. The reaction mixture was partitioned between the indicated solvent and water. Organic extracts were combined and washed in the indicated order using the following aqueous solutions; water, 1 N aqueous sodium hydroxide solution (1 N NaOH), 5% aqueous NaHCO 3 solution (aqueous NaHCO 3 ), 1 N hydrochloric acid (HCl) and brine. Extracts were dried over anhydrous magnesium sulfate (MgSO 4 ), filtered and evaporated in vacuo.
Chromatographic separations were carried out on Silica gel 60 (0.063-0.200 mm, E. Merck) or ODS (CPO-273L R , pre-packed column, 22 mmϫ 300 mm, Kusano Kagaku Kikai Co.) using the indicated eluents.
Chloromethyl pivalate (4c), bromomethyl acetate (5a) were purchased from Aldrich Chemical Company, Inc.. Chloromethyl isobutylate (4b), 14) chloromethyl propyl carbonate (4e), chloromethyl isopropyl carbonate (4f), 15) ethyl iodomethyl carbonate (6d) 16) were prepared according to the literature.
Chloromethyl (1,3-Dioxan-5-yl) Carbonate (4g) A solution of chloromethyl chloroformate (25 g) in diethyl ether (Et 2 O, 50 ml) was added dropwise to a stirred solution of glycerol formal (14 g) and pyridine (15 g) in Et 2 O (400 ml) over a period of 10 min at 0°C. After stirring for 20 h, the precipitate was removed by filtration. The filtrate was worked up (Et 2 O; brine). The residue was purified by silica gel flush column chromatography (AcOEt-hexane, 1 : 5→1 : 3, v/v) to give 4g (1.7 g, 5%) as a colorless oil. [2-(N-Acetylamino)ethyl] chloromethyl carbonate (4i) and 3-benzyloxypropoxy chloromethyl carbonate (4j) were prepared from the corresponding alcohols (N-acethylethanolamine, 3-benzyloxypropanol 17) ) by the same method as described above. (1,3-Dioxan-5-yl) Iodomethyl Carbonate (6g) A mixture of 4g (1.7 g), sodium iodide (5.1 g) and MeCN (40 ml) was stirred at 60°C for 2 h. The resulting mixture was concentrated in vacuo. The residue was worked up (Et 2 O; 5% aqueous sodium thiosulfate solution, water, brine) to give 6g (3.2 g, 100%) as a pale yellow oil. Iodomethyl propyl carbonate (6e), [2-(N-acetylamino) ethyl] iodomethyl carbonate (6i) and 3-benzyloxypropoxy iodomethyl carbonate (6j) were prepared from the corresponding chloromethyl carbonates 4e, i, j by the same method as described above. 6e (88%): in MeCN (2 ml) was stirred for 7 h at 80°C under an argon atmosphere. The reaction mixture was diluted with MeCN (11 ml), and the resulting mixture was stirred at 80°C until the clear solution was obtained. After having been cooled to room temperature (r.t.), silica gel (400 mg) was added, and the mixture was stirred for 10 min at r.t. The silica gel was filtered off and washed with MeCN-tetrahydrofuran (THF) (1 : 1, v/v, 2 mlϫ3). The mother liquor and the washings were combined, and brine (10 ml) was added. The resulting mixture was stirred for 30 min at r.t., and the organic layer was separated. The same operations as above, the addition of brine (10 ml) to the organic layer followed by the stirring for 30 min at r.t. and the subsequent separation of the organic layer, were performed further three times. The organic layer was dried over MgSO 4 , and the solvent was distilled off under reduced pressure. The residue was dissolved in THF (3 ml), and the solution was allowed to stand for 5 h at r.t. The precipitate (179 mg) was collected by filtration and dissolved in methanol (MeOH)-THF (1 : 1, v/v, 4 ml). The solution was concentrated in vacuo and the residue was dissolved in THF (2 ml). The solution was allowed to stand for 5 h at r.t. The precipitate was collected by filtration and dissolved in ethanol (EtOH)-acetone (12 : 1, v/v, 6.5 ml). The resulting solution was concentrated in vacuo to a volume of ca. 2 ml and allowed to stand for 3 h at r.t. The precipitate was collected by filtration to give the unhydrated form of 2a (126 mg, 51%) as a white crystalline powder. Compound 2a (0.63 g) obtained above was recrystallized from water (10 ml) to give the hydrate form (0.61 g) as a white crystalline powder. (1.37 g) and acetone (20 ml) was refluxed for 50 h. The resulting mixture was concentrated in vacuo and diisopropylether (isoPr 2 O, 10 ml) was added to the residue. The precipitate was collected by filtration and purified by ODS column chromatography (MeOH-H 2 O, 3 : 2, v/v) to give 2b (0.15 g, 24%) as a white amorphous powder. This powder (50 mg) was crystallized from saline (1 ml) to obtain 2b (41 mg) as a white crystalline powder. Table 1 ) A mixture of 1 (1.31 g, 2.72 mmol), 6d (1.25 g, 5.43 mmol) and MeCN (15 ml) was stirred at 60°C for 14 h under an argon atmosphere. The resulting mixture was concentrated in vacuo. The residue was purified by silica gel flush column chromatography (AcOEt→acetone→acetone-EtOH, 4 : 1, v/v) followed by ODS column chromatography (MeOH-H 2 O, 3 : 2, v/v) to give the iodide salt (1.1 g) as a pale yellow amorphous powder. The iodide salt (1.1 g) was then ion-exchanged using Dowex 1ϫ8 Cl Ϫ (water) followed by crystallization from EtOH to give 2d (0.7 g, 42%) as a white crystalline powder. 0 g ) was allowed to react with 6e (0.9 g) in a manner similar to that described for the synthesis of 2d to obtain the iodide (1.0 g) as a pale yellow amorphous powder. This iodide (0.3 g) was dissolved in THF-AcOEt (3/1, 100 ml) and ionexchanged by mixing with brine (50 mlϫ4). The organic layer was dried over MgSO 4 , and concentrated in vacuo followed by crystallization from EtOH-acetone to give 2e (0.09 g, 22% from 1) as a white crystalline powder. Table 1 ) The reaction of 1 (0.5 g) with 4f (3.17 g) was carried out in a manner similar to that described for the synthesis of 2c. Compound 2f (110 mg, 17%) was obtained as a white crystalline powder (recrystallized from AcOEt-acetone). Table 1 ) The reaction of 1 (1.0 g) with 6g (0.9 g) was carried out in a manner similar to that described for the synthesis of 2d to obtain the iodide (4.22 g) as a pale yellow amorphous powder. This iodide salt (1 g) was subjected to column chromatography on Dowex 1ϫ8 Cl Ϫ (water). The eluate was lyophilized to obtain 2g (0.23 g, 27%) as a white amorphous powder. This powder (0.15 g) was crys-
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